RD-MolPack technology for the constitutive production of self-inactivating lentiviral vectors pseudotyped with the nontoxic RD114-TR envelope

To date, gene therapy with transiently derived lentivectors has been very successful to cure rare infant genetic diseases. However, transient manufacturing is unfeasible to treat adult malignancies because large vector lots are required. By contrast, stable manufacturing is the best option for high-...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Mol Ther Methods Clin Dev
Main Authors: Marin, Virna, Stornaiuolo, Anna, Piovan, Claudia, Corna, Stefano, Bossi, Sergio, Pema, Monika, Giuliani, Erica, Scavullo, Cinzia, Zucchelli, Eleonora, Bordignon, Claudio, Rizzardi, Gian Paolo, Bovolenta, Chiara
פורמט: Artigo
שפה:Inglês
יצא לאור: Nature Publishing Group 2016
נושאים:
Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC4863723/
https://ncbi.nlm.nih.gov/pubmed/27222840
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/mtm.2016.33
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים